Clinical Trials Logo

Hepatitis, Chronic clinical trials

View clinical trials related to Hepatitis, Chronic.

Filter by:

NCT ID: NCT03585322 Completed - Chronic Hepatitis B Clinical Trials

APG-1387 Study of Safety, Tolerability ,PK/PD in Patients With Chronic Hepatitis B

Start date: July 4, 2018
Phase: Phase 1
Study type: Interventional

This study is a Multiple Ascending Dose study to Explore the Tolerability, Safety and Pharmacokinetics/Pharmacodynamics of APG-1387 in Chronic Hepatitis B Patients.

NCT ID: NCT03577171 Completed - Chronic Hepatitis B Clinical Trials

A Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Participants With Chronic Hepatitis B Virus Infection (cHBV)

Start date: June 19, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if ABI-H0731 given in combination with a standard of care (SOC) entecavir (ETV) is safe and effective in participants with chronic hepatitis B infection (cHBV)

NCT ID: NCT03576066 Completed - Chronic Hepatitis B Clinical Trials

A Study Evaluating ABI-H0731 as Adjunctive Therapy in Participants With Chronic Hepatitis B Infection

Start date: June 11, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if ABI-H0731 given in combination with a standard of care (SOC) hepatitis B virus (HBV) nucleos(t)ide reverse transcriptase inhibitor (NUC) medication is safe and effective in participants with chronic hepatitis B virus infection (cHBV).

NCT ID: NCT03546621 Completed - Clinical trials for Chronic Hepatitis D Infection With Hepatitis B

A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D

Start date: February 16, 2016
Phase: Phase 2
Study type: Interventional

This is a multicenter, open-label, randomized clinical trial to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination with Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients with Chronic Hepatitis D

NCT ID: NCT03537274 Completed - Hepatitis C Clinical Trials

Efficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016)

Start date: August 5, 1997
Phase: Phase 2/Phase 3
Study type: Interventional

This study will determine the efficacy of PEG-Intron (SCH 54031) in participants with chronic Hepatitis C virus (HCV) infection who have not been previously treated with interferon. Participants are randomized to receive one of three doses of PEG-Intron (0.5, 1.0, and 1.5 mg/kg) or Interferon Alfa-2B for 48 weeks. The primary objective of this study is to evaluate the efficacy of PEG-Intron (compared to Interferon Alfa-2B) with respect to response based on loss of detectable HCV ribonucleic acid (HCV-RNA) and normalization of alanine transaminase (ALT) level after 24 weeks of therapy and at 24 weeks of follow-up.

NCT ID: NCT03501550 Completed - Chronic Hepatitis C Clinical Trials

Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)

Start date: June 26, 2018
Phase: Phase 2
Study type: Interventional

Open label phase 2a study of two week treatment with CDI-31244 and sofosbuvir and veltapasvir followed by four week treatment of sofosbuvir and velpatasvir in individuals with chronic hepatitis C (HCV) genotype 1 (GT1) infection

NCT ID: NCT03491553 Completed - Chronic Hepatitis B Clinical Trials

Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B

Start date: April 6, 2018
Phase: Phase 2
Study type: Interventional

The primary objectives of this study are to evaluate the safety, tolerability and antiviral activity of selgantolimod (formerly GS-9688) in virally suppressed chronic hepatitis B (CHB) adults on oral antiviral (OAV) agents.

NCT ID: NCT03490097 Completed - Metabolic Syndrome Clinical Trials

Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir Combination

Start date: December 1, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of the study is to determine if statin can affect the clinical outcome of chronic hepatitis C patients receiving Sofosbuvir/Daclatasvir/Ribavirin combination

NCT ID: NCT03485846 Completed - Clinical trials for Chronic Hepatitis C Genotype 1b

Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Daclatasvir in Treatment-Naїve Patients With Chronic Hepatitis C Genotype 1b

Start date: November 27, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to confirm that combination of Narlaprevir, Ritonavir and Daclatasvir is safe and highly effective regimen in treatment-naїve patients with chronic hepatitis C (HCV) genotype 1b infection.

NCT ID: NCT03462173 Completed - Chronic Hepatitis c Clinical Trials

The Safety, Tolerability and Pharmacokinetic Study of Yimitasvir in Healthy Adults Subjects

Start date: December 3, 2014
Phase: Phase 1
Study type: Interventional

The Safety, Tolerability and Pharmacokinetic Study of Chronic Hepatitis C Treatment Drug Yimitasvir in Healthy Adults Subjects.